These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 18703528)

  • 1. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    Rheumatology (Oxford); 2008 Oct; 47(10):1489-92. PubMed ID: 18703528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin.
    Chapuy-Regaud S; Nogueira L; Clavel C; Sebbag M; Vincent C; Serre G
    Clin Exp Immunol; 2005 Mar; 139(3):542-50. PubMed ID: 15730401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of HLA-DRB alleles on the subclass titres of antibodies against citrullinated peptides.
    Engelmann R; Eggert M; Neeck G; Mueller-Hilke B
    Rheumatology (Oxford); 2010 Oct; 49(10):1862-6. PubMed ID: 20584722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
    Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
    Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis?
    Koivula MK; Aman S; Karjalainen A; Hakala M; Risteli J
    Ann Rheum Dis; 2005 Oct; 64(10):1443-50. PubMed ID: 16162901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
    Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
    Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders.
    Anzilotti C; Riente L; Pratesi F; Chimenti D; Delle Sedie A; Bombardieri S; Migliorini P
    Rheumatology (Oxford); 2007 Oct; 46(10):1579-82. PubMed ID: 17717033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.